Emerging nanotechnology for Alzheimer's disease: From detection to treatment
Abstract
Alzheimer's disease (AD), one of the most common chronic neurodegenerative diseases, is characterized by memory impairment, synaptic dysfunction, and character mutations. The pathological features of AD are Aβ accumulation, tau protein enrichment, oxidative stress, and immune inflammation. Since the pathogenesis of AD is complicated and ambiguous, it is still challenging to achieve early detection and timely treatment of AD. Due to the unique physical, electrical, magnetic, and optical properties of nanoparticles (NPs), nanotechnology has shown great potential for detecting and treating AD. This review provides an overview of the latest developments in AD detection via nanotechnology based on NPs with electrochemical sensing, optical sensing, and imaging techniques. Meanwhile, we highlight the important advances in nanotechnology-based AD treatment through targeting disease biomarkers, stem-cell therapy and immunotherapy. Furthermore, we summarize the current challenges and present a promising prospect for nanotechnology-based AD diagnosis and intervention.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Electrochemical and optical biosensor-based nanodiagnostics enable ultrasensitive detection of Alzheimer's disease biomarkers in biological fluids.
“Electrochemical and optical biosensor-based nanodiagnostics also enable ultrasensitive detection of AD biomarkers in biological fluids, offering promising prospects for non-invasive disease monitoring [128].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [128]
The citation lists haven’t been fetched yet
References 175 · Cited by 44
- Authors
- Song, N., Sun, S., Chen, K., Wang, Y., Wang, H., Meng, J., Guo, M., Zhang, X.-D., & Zhang, R.
- Affiliations
- Tianjin Chengjian University (CN)
- Tianjin University (CN)
- Shanxi Medical University (CN)
- Corresponding author
- Guo, Meili
- Zhang, Ruiping
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2023-08
- Volume
- 360
- Pages
- 392-417
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W4383483402
- Cited by
- 44
- References
- 175
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 16 · 2023: 4
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- Alzheimer's disease, nanotechnology, nanoparticles, early diagnosis, amyloid-beta, tau protein, oxidative stress, neuroinflammation, electrochemical sensing, optical sensing, nanomedicine, stem cell therapy, immunotherapy
- MeSH terms
- Alzheimer Disease, Humans, Amyloid beta-Peptides, Oxidative Stress, Nanotechnology, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
